Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia

American Heart Journal

Volumn 137, Issue 3, 1999, Pages 458-462

  Strauss, William E ^a   Lapsley, Diane ^b   Michael Gaziano, J ^b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032974845     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70492-8     Document Type: Article

References (20)

1. Physician's Desk Reference. Montvale NJ: Medical economics data production Co; 1994.
2. Denke MA, Grundy SG. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 1995;155:393-9.
3. Schrott HG, Stein EA, Dujovne CA. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995;75:34-9.
4. Rubenstein A, Lurie Y, Groskop I, et al. Cholesterol lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200-240 mg/dl. Am J Cardiol 1991;68:1123-6.
5. Richter WO, Jacob BG, Schwandt P. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins. Int J Tissue React 1991;13:107-10.
6. McPherson R, Bedaro J, Connelly P. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992;14:276-90.
7. Ditschuneit HH, Kuhn K, Ditschuneit H. Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1991;409(suppl 1):S27-32.
8. The lovastatin pravastatin study group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993;71:810-5.
9. Bradford RH, Shear CL, Chremos AN. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991;151:43-9.
10. Davidson MH, Stein, Dujovne CA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
11. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
12. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-82.
13. Warnick GR, Benderson J, Albers JJ. Dextran-sulfate-Mg2+ precipitation for quantitation of high density lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
14. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP II). JAMA 1993;269:3015-23.
15. National cholesterol education program expert panel. Report of the national cholesterol education program expert panel on detection evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
16. Jones PH, Farmer JA, Crossman MD. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14:146-51.
17. Hunninghake DB, Knopp RH, Schonfeld G. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 1990;85:81-9.
18. Arca M, Vega GL, Grundy SC. Hypercholesterolemia in postmenopausal women: metabolic defects and response to low-dose lovastatin. JAMA 1994;271:453-9.
19. Karlsson FO, Garber AJ. Benefits and risks of combination lipid-lowering therapy for combined hyperlipidemias. Cardiovasc Rev Reports 1997;19:11-2.
20. Drug topics red book. Montvale, NJ: Medical Economics Data; February 1995 update.